Sign in
4

Changes in Ownership

CytomX Therapeutics, Inc. Filed Acc 0001140361-17-040975

Chief Financial Officer sold 2,500 shares at $20.00 ($50,000)

From the SEC's structured data for this filing

Trades in this filing

RAY DEBANJAN · Chief Financial Officer

Table I: Non-derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2017-11-01 Sale : show line 1 in the form −2,500 $20.00 $50,000 12,126 D
Open-market sales · 2,500 sh · avg $20.00 · $50,000
Loading xslF345X03/doc1.xml…